Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET.
A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.establishmentlabs.com. In-person attendance at the event is limited and requires advanced registration. Please email: ir@establishmentlabs.com for further information.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
AIRO Announces Pricing of Its Initial Public Offering
ALBUQUERQUE, N.M. & MONTREAL & STØVRING, Denmark & WASHINGTON, June 13, 2025--(BUSINESS WIRE)--AIRO Group Holdings, Inc. ("AIRO"), a company specializing in advanced aerospace and defense technologies, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $10.00 per share. All shares of common stock are being offered by AIRO. The gross proceeds to AIRO from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AIRO, are expected to be $60.0 million. AIRO has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares (solely to cover over-allotments, if any) of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol "AIRO" on June 13, 2025, and the offering is expected to close on June 16, 2025, subject to the satisfaction of customary closing conditions. AIRO currently intends to use the net proceeds it receives from this offering, together with its existing cash and restricted cash to support growth initiatives across each segment, repay debt and general corporate purposes. Cantor, BTIG, and Mizuho are acting as joint lead book-running managers for the proposed offering and Bancroft Capital is acting as book-running manager for the proposed offering. A registration statement relating to the offering of securities was declared effective by the U.S. Securities and Exchange Commission on June 12, 2025. The offering is being made only by means of a final prospectus. When available, copies of the final prospectus relating to the offering may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@ BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at prospectusdelivery@ and Mizuho Securities USA LLC, Attention: U.S. ECM Desk, 1271 Avenue of the Americas, New York, New York 10020, or by email at US-ECM@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About AIRO AIRO is a technologically differentiated aerospace, autonomy, and air mobility platform targeting 21st century aerospace and defense opportunities. AIRO is organized into four operating segments, each of which represents a critical growth vector in the aerospace and defense market: Drones, Avionics, Training, and Electric Air Mobility. Forward-Looking Statements The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as "believes," "expects," "may," "will," "should," "seeks," "intends," "plans," "estimates," or "anticipates," or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to AIRO's expected gross proceeds from the initial public offering, the expected use of proceeds from such initial public offering, the expected date for AIRO's common stock to begin trading on the Nasdaq Global Market and the expected closing of the initial public offering. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. AIRO's expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. AIRO undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. View source version on Contacts Dan JohnsonAIRO Group Holdings, Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
StopTheBleed.com Launches As A Dedicated Resource for Bleeding Control Kits
LELAND, N.C., June 12, 2025 /PRNewswire/ -- In recognition of the 10th anniversary of the STOP THE BLEED® initiative, Rescue Essentials is proud to announce the launch of a streamlined e-commerce destination for officially licensed STOP THE BLEED® kits and mass casualty response solutions. Designed to help organizations of all sizes prepare for bleeding emergencies, provides expertly curated kits for schools, public buildings, factories, offices, and anywhere else traumatic bleeding can happen. Each kit is built at our North Carolina facility with trusted components from Rescue Essentials and other leading manufacturers such as SAM Medical and North American Rescue " makes it easier than ever for people to find the exact bleeding control kits they need, whether to comply with local legislation or simply to be better prepared," said Jim Seidel, Rescue Essentials CEO. "Our team is here to assist with product selection, identify applicable state requirements, and even help customers locate available grant funding to support their preparedness goals." As a licensed partner of the U.S. Department of Defense's STOP THE BLEED® program, Rescue Essentials is committed to supporting this international public health initiative, which empowers bystanders to take action and save lives in the critical moments following a traumatic injury. represents Rescue Essentials' continued dedication to delivering high-quality, accessible medical response products and training support to first responders, safety officials and everyday heroes across the country. About Rescue Essentials Since 2007, Rescue Essentials has remained focused on its original goal — to offer top quality tactical, emergency, combat, and outdoor medical products at affordable prices, delivered in a timely manner. Rescue Essentials' core capabilities include the design, manufacture, and assembly of purpose-built trauma and medical kits for law enforcement, EMS and government agencies. Rescue Essentials, a division of Tri-Tech Forensics, Inc., is based in Leland, N.C. View original content to download multimedia: SOURCE Tri-Tech Forensics
Business Wire
31 minutes ago
- Business Wire
AIRO Announces Pricing of Its Initial Public Offering
ALBUQUERQUE, N.M. & MONTREAL & STØVRING, Denmark & WASHINGTON--(BUSINESS WIRE)--AIRO Group Holdings, Inc. ('AIRO'), a company specializing in advanced aerospace and defense technologies, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $10.00 per share. All shares of common stock are being offered by AIRO. The gross proceeds to AIRO from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by AIRO, are expected to be $60.0 million. AIRO has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares (solely to cover over-allotments, if any) of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market under the ticker symbol 'AIRO' on June 13, 2025, and the offering is expected to close on June 16, 2025, subject to the satisfaction of customary closing conditions. pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $10.00 per share Share AIRO currently intends to use the net proceeds it receives from this offering, together with its existing cash and restricted cash to support growth initiatives across each segment, repay debt and general corporate purposes. Cantor, BTIG, and Mizuho are acting as joint lead book-running managers for the proposed offering and Bancroft Capital is acting as book-running manager for the proposed offering. A registration statement relating to the offering of securities was declared effective by the U.S. Securities and Exchange Commission on June 12, 2025. The offering is being made only by means of a final prospectus. When available, copies of the final prospectus relating to the offering may be obtained from: Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@ BTIG, LLC, 65 East 55th Street, New York, New York 10022, or by email at prospectusdelivery@ and Mizuho Securities USA LLC, Attention: U.S. ECM Desk, 1271 Avenue of the Americas, New York, New York 10020, or by email at US-ECM@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About AIRO AIRO is a technologically differentiated aerospace, autonomy, and air mobility platform targeting 21st century aerospace and defense opportunities. AIRO is organized into four operating segments, each of which represents a critical growth vector in the aerospace and defense market: Drones, Avionics, Training, and Electric Air Mobility. Forward-Looking Statements The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as 'believes,' 'expects,' 'may,' 'will,' 'should,' 'seeks,' 'intends,' 'plans,' 'estimates,' or 'anticipates,' or similar expressions which concern our strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to AIRO's expected gross proceeds from the initial public offering, the expected use of proceeds from such initial public offering, the expected date for AIRO's common stock to begin trading on the Nasdaq Global Market and the expected closing of the initial public offering. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. AIRO's expectations, beliefs and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. AIRO undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
